Many algorithms claiming to identify melanoma better than dermatologists are trained on retrospective datasets, which is not reflective of real-world clinical practice, said Jonathan Kentley, MBBS, MSc, research fellow at Memorial Sloan Kettering Cancer Center.
Many algorithms claiming to identify melanoma better than dermatologists are trained on retrospective datasets, which is not reflective of real-world clinical practice, said Jonathan Kentley, MBBS, MSc, research fellow at Memorial Sloan Kettering Cancer Center.
Transcript
What can you tell us about the Skin Analytics study evaluating the effectiveness of an image-analyzing algorithm in identifying certain skin conditions?
The issue with a lot of these algorithms that are claiming they're much better than dermatologists, they've all been trained on retrospective data sets of images—which doesn't really mirror clinical practice and how they're going to be rolled out in reality—whereas Skin Analytics is one of the few companies that have really gone through the effort to make a well-controlled prospective trial. They've already done one in the UK, across 7 different hospitals, with about 500 lesions that they imaged, and showed that, actually, it was sort of on par with dermatologists at detecting melanoma.
But now that they have a breakthrough FDA authorization and a CE mark, they're embarking on a much bigger trial across Europe and the US. I think it'll be really interesting to see the results of this, and as with any medical device or medication, we really need rigorous clinical trials to validate them in clinical practice, so I'm excited to see the results.
Sustaining Compassionate Trauma Care Across Communities
September 30th 2024September is National Recovery Month, and we are bringing you another limited-edition month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In our final episode, we speak with Lyndra Bills, MD, and Shari Hutchison, MS.
Listen
A Novel Approach to Chronic GVHD With Axatilimab: Dr Daniel Wolff
October 18th 2024The latest therapy approved to treat chronic graft-versus-host disease (GVHD) has a new target different than the other approved therapies. Daniel Wolff, MD, also discusses future research on axatilimab to treat chronic GVHD earlier.
Read More
Bimekizumab Poised to Tackle Unmet HS Treatment Needs
October 18th 2024Hidradenitis suppurativa (HS) is an inflammatory, chronic disease with very high symptom and physical burdens, and it can get progressively worse over time if it's inadequately treated, explained Amit Garg, MD, founding chair, Department of Dermatology, Northwell Health.
Read More